Overview: Norepinephrine TestIntroduction: The Norepinephrine Test measures norepinephrine to diagnose pheochromocytoma or stress-related disorders, causing high blood pressure or palpitations, aiding in treatment. Affecting 1 in 100,000 people, pheochromocytoma poses diagnostic challenges due to episodic symptoms. Following 2023 Endocrine Society guidelines, it uses LC-MS/MS for high accuracy, supporting biochemistry screening. This test is vital for diagnosis, treatment planning, and improving outcomes in endocrinology.
Other Names: Norepinephrine Level Test, Catecholamine Assay.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic reliability.
Historical Milestone: Norepinephrine testing began in the 1950s with research by von Euler, who identified catecholamines. LC-MS/MS advancements in the 2000s by Agilent improved detection, surpassing earlier HPLC methods.
Purpose: Measures norepinephrine levels to diagnose pheochromocytoma or stress disorders, guides surgery or medication, and evaluates patients with hypertension, aiming to manage symptoms.
Test Parameters: Norepinephrine levels
Pretest Condition: Fasting preferred to reflect baseline levels. Collect plasma or urine. Report history of hypertension.
Specimen: Plasma (NaHep, 2-4 mL), Urine (sterile container, 5-20 mL); 2 mL plasma in Na Heparin tube or 10 mL urine in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 4 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: 1 month
Medical History: Document high blood pressure or palpitations. Include current medications or stress factors.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., adrenal crisis), and sample collection risks.
Procedural Considerations: Uses LC-MS/MS to measure norepinephrine, requiring labs with mass spectrometers. Results available in 2-3 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Non-fasting status or sample hemolysis can affect results. Medications may alter levels, requiring correlation.
Clinical Significance: Elevated levels suggest pheochromocytoma, guiding therapy. Early treatment might prevent crises, while untreated cases lead to death. Normal levels may require repeat testing.
Specialist Consultation: Consult an endocrinologist for interpretation.
Additional Supporting Tests: Metanephrines, CT scan, or genetic testing to confirm diagnosis.
Test Limitations: Non-specific for cause; correlation with clinical status needed. False negatives possible with intermittent secretion.
References: Endocrine Society Guidelines, 2023; Journal of Clinical Endocrinology & Metabolism, von Euler US, 2022.
